Abstract
Antipsychotics are widely used for the treatment of behavioral and psychological symptoms of dementia (BPSD). Concerns have been raised in the literature over the safety of antipsychotics, with suggestions of an increased risk of mortality. The objective of this study was to determine the all-cause mortality risk associated with antipsychotic use among Alzheimer’s disease (AD) patients. A new-user study was conducted in a multicentric prospective cohort, composed of 534 community-dwelling mild-to-moderate AD patients recruited in 16 French memory centers. A survival analysis using a Cox proportional hazards model assessed hazard ratios (HRs) for death according to either first or second generation antipsychotic use (time-varying variable). Among the 534 patients, 102 new users were identified throughout the 3.5 year-follow-up period and 113 deaths occurred. The main antipsychotics used were risperidone and tiapride. Unadjusted and sociodemographic-adjusted (age, gender, center) analyses suggested an increased risk of death with antipsychotic use (HR: 1.84; 95% CI: [1.09-3.09] and HR: 1.93; 95% CI: [1.15-3.25]) respectively). However, antipsychotic use did not appear to be an independent predictive factor of death when dementia severity (cognitive status) was accounted for during fully adjusted multivariate analyses (HR: 1.12; 95% CI: [0.59-2.12]). Antipsychotic use may be associated with an increased risk of mortality, but to a lesser extent than several other factors which were found to be significant predictors of mortality (age, male gender, cognitive score, recent hospitalisation, medical aid). To date, antipsychotic risks outweigh their benefits in BPSD for which non-pharmacological approaches remain the first-line strategy and should be privileged.
Keywords: Antipsychotic agents, mortality, Alzheimer disease, dementia, cohort studies, antipsychotics, psychiatric disorders, neuroendocrine disease.
Current Alzheimer Research
Title:Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Volume: 9 Issue: 9
Author(s): Virginie Gardette, Maryse Lapeyre-Mestre, Nicola Coley, Christelle Cantet, Jean-Louis Montastruc, Bruno Vellas and Sandrine Andrieu
Affiliation:
Keywords: Antipsychotic agents, mortality, Alzheimer disease, dementia, cohort studies, antipsychotics, psychiatric disorders, neuroendocrine disease.
Abstract: Antipsychotics are widely used for the treatment of behavioral and psychological symptoms of dementia (BPSD). Concerns have been raised in the literature over the safety of antipsychotics, with suggestions of an increased risk of mortality. The objective of this study was to determine the all-cause mortality risk associated with antipsychotic use among Alzheimer’s disease (AD) patients. A new-user study was conducted in a multicentric prospective cohort, composed of 534 community-dwelling mild-to-moderate AD patients recruited in 16 French memory centers. A survival analysis using a Cox proportional hazards model assessed hazard ratios (HRs) for death according to either first or second generation antipsychotic use (time-varying variable). Among the 534 patients, 102 new users were identified throughout the 3.5 year-follow-up period and 113 deaths occurred. The main antipsychotics used were risperidone and tiapride. Unadjusted and sociodemographic-adjusted (age, gender, center) analyses suggested an increased risk of death with antipsychotic use (HR: 1.84; 95% CI: [1.09-3.09] and HR: 1.93; 95% CI: [1.15-3.25]) respectively). However, antipsychotic use did not appear to be an independent predictive factor of death when dementia severity (cognitive status) was accounted for during fully adjusted multivariate analyses (HR: 1.12; 95% CI: [0.59-2.12]). Antipsychotic use may be associated with an increased risk of mortality, but to a lesser extent than several other factors which were found to be significant predictors of mortality (age, male gender, cognitive score, recent hospitalisation, medical aid). To date, antipsychotic risks outweigh their benefits in BPSD for which non-pharmacological approaches remain the first-line strategy and should be privileged.
Export Options
About this article
Cite this article as:
Gardette Virginie, Lapeyre-Mestre Maryse, Coley Nicola, Cantet Christelle, Montastruc Jean-Louis, Vellas Bruno and Andrieu Sandrine, Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity, Current Alzheimer Research 2012; 9 (9) . https://dx.doi.org/10.2174/156720512803569037
DOI https://dx.doi.org/10.2174/156720512803569037 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Hormones in the Mentally Disturbed Brain: Steroids and Peptides in the Development and Treatment of Psychopathology
Central Nervous System Agents in Medicinal Chemistry Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment
Current Alzheimer Research Blood Pressure and Cognitive Impairment in the Elderly
Current Hypertension Reviews Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Editorial (An Idea Whose Time Has Come? An African Foresight Observatory on Genomics Medicine and Data-Intensive Global Science)
Current Pharmacogenomics and Personalized Medicine Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models
Current Pharmaceutical Design Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease
Current Neuropharmacology EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Editorial [Hot Topic: Brain Resilience and Plasticity in the Face of Alzheimer Pathology (Guest Editor: Ira Driscoll & Juan Troncoso)]
Current Alzheimer Research The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research